UCLA and Caltech integrated Cardiovascular Medicine for Bioengineers (iCMB)

加州大学洛杉矶分校和加州理工学院生物工程师综合心血管医学 (iCMB)

• 批准号: 10469660
• 负责人: Tzung K Hsiai
• 金额: $ 30.54万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10469660
• 关键词: Biomedical Engineering; Cardiovascular system; Medicine

ABSTRACT This T32 program represents a new paradigm for training biophysical scientists and engineers to traverse cardiovascular medicine. The convergence of engineering with medicine is transforming clinical and patient care via advances in flexible electronics for sensing and imaging, coupled with machine learning, which has introduced new innovations to confront the rising endemic of cardiometabolic disorders. The University of California at Los Angeles (UCLA) and the California Institute of Technology (Caltech) are partnering to develop the UCLA/Caltech integrated Cardiovascular Medicine for Bioengineers (iCMB) Program, that will be formalized into a 2-year, structured curriculum with an emphasis on recruiting the under-represented post- doctoral engineers or biophysical scientists into leadership roles in academia and industry. The approach is to strengthen individualized training in 1) advanced sensing or 2) imaging coupled with machine learning to address 3) cardiometabolic disease. The iCMB program will be built upon two successful Caltech and UCLA joint training programs: the Medical Scientist Training Program (MSTP) for MD-PhD students and the unique Subspecialty Training and Advanced Research Program (STAR) for fellowship-level physicians to obtain a PhD. The partnerships with the industry leaders from Amgen, Johnson & Johnson, Medtronic, and Edwards Lifesciences have enriched our internship, mentorship, and leadership programs. Both the Caltech Diversity Center and UCLA Faculty Diversity & Development Office have supported workshops on Science Technology Engineering & Mathematics (STEM) for women and under-represented minorities. To implement this iCMB Program, we have developed a novel mentoring and self-evaluating structure in the inclusion of 24 seasoned mentors, 4 emerging faculty, 22 Clinical Faculty (42% female), and 10 industry leaders. Each iCMB scholar will have co-mentorships: a primary mentor from cardiometabolic medicine and a secondary from enabling technologies or industry. In Year 1, iCMB scholars will develop fundamental knowledge in advanced imaging, sensors, or computation and didactic training for ethics in biomedical research and publications. In Year 2, iCMB scholar will have an option 1) to participate in a certificate in Pathways in Clinical and Translational Research from the UCLA Clinical Translational Science Institute (CTSI) or Law and Technology for FDA regulatory science (BE188/299); and/or 2) to participate in UCLA CTSI-sponsored professional development in preparation for an academic or industry career. Both Caltech and UCLA Deans have committed matching funds for each iCMB scholar. Our Vice Provost for UCLA Graduate Education has also committed supplemental trainee support to enhance the diversity of trainees. Therefore, the complementary and synergistic strengths of the Caltech/UCLA iCMB Program provide a new infusion of workforce prepared to solve the worldwide endemic of cardiometabolic disease.

抽象的 这个 T32 项目代表了培训生物物理科学家和工程师穿越的新范例 心血管医学。工程与医学的融合正在改变临床和患者 通过用于传感和成像的柔性电子器件的进步以及机器学习来进行护理，这已经 推出新的创新来应对日益流行的心脏代谢疾病。大学 加州大学洛杉矶分校 (UCLA) 和加州理工学院 (Caltech) 正在合作开发 加州大学洛杉矶分校/加州理工学院生物工程师综合心血管医学 (iCMB) 计划 正式化为为期 2 年的结构化课程，重点是招募代表性不足的后 博士工程师或生物物理学科学家在学术界和工业界发挥领导作用。方法 是加强1）先进传感或2）成像与机器结合的个性化培训 学习解决3）心脏代谢疾病。 iCMB 计划将建立在两个成功的基础上 加州理工学院和加州大学洛杉矶分校联合培训项目：医学博士-博士医学科学家培训项目 (MSTP) 学生和独特的专科培训和高级研究计划（STAR） 医生获得博士学位。与安进 (Amgen)、强生 (Johnson & Johnson) 等行业领导者的合作伙伴关系， 美敦力 (Medtronic) 和爱德华兹生命科学 (Edwards Lifesciences) 丰富了我们的实习、指导和领导力项目。 加州理工学院多样性中心和加州大学洛杉矶分校教师多样性与发展办公室都支持 为女性和弱势群体举办科学技术工程与数学 (STEM) 讲习班 少数民族。为了实施这个 iCMB 计划，我们开发了一种新颖的指导和自我评估方法 结构包括 24 名经验丰富的导师、4 名新兴教师、22 名临床教师（42% 为女性）和 10 名 行业领导者。每位 iCMB 学者都会有共同导师：一位来自心脏代谢的主要导师 医学和辅助技术或工业的辅助。在第一年，iCMB 学者将开发 先进成像、传感器或计算的基础知识以及伦理道德培训 生物医学研究和出版物。在第 2 年，iCMB 学者将可以选择 1) 参加 加州大学洛杉矶分校临床转化科学临床和转化研究途径证书 FDA 监管科学研究所 (CTSI) 或法律与技术 (BE188/299)；和/或 2) 参与 加州大学洛杉矶分校 CTSI 赞助的专业发展，为学术或行业职业生涯做好准备。两个都 加州理工学院和加州大学洛杉矶分校的院长已承诺为每位 iCMB 学者提供配套资金。我们的加州大学洛杉矶分校副教务长 研究生教育还承诺提供补充实习生支持，以增强实习生的多样性。 因此，加州理工学院/加州大学洛杉矶分校 iCMB 项目的互补和协同优势提供了一个新的机会。 注入劳动力准备解决全球范围内流行的心脏代谢疾病。